Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase

Trends in Molecular Medicine

Volumn 17, Issue 7, 2011, Pages 395-403

  Perl, Andras ^a   Hanczko, Robert ^a   Telarico, Tiffany ^a   Oaks, Zachary ^a   Landas, Steve ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; PENTOSE PHOSPHATE; TRANSALDOLASE; TRANSCRIPTION FACTOR;

CARCINOGENESIS; CELL SPECIFICITY; CELL TYPE; CLINICAL PRACTICE; ENZYME ACTIVATION; FATTY LIVER; GENETIC DISORDER; GLUCOSE METABOLISM; HEMOLYTIC ANEMIA; HUMAN; INFLAMMATION; MALE INFERTILITY; METABOLIC REGULATION; MITOCHONDRIAL TOXICITY; NEOPLASM; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; REVIEW;

ACETYLCYSTEINE; ANIMALS; AUTOIMMUNITY; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; FATTY LIVER; GLUCOSE; HUMANS; INFERTILITY, MALE; INFLAMMATION; MALE; MITOCHONDRIA; OXIDATIVE STRESS; PENTOSE PHOSPHATE PATHWAY; SPERM MOTILITY; TRANSALDOLASE;

EID: 79960221714     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.01.014     Document Type: Review

References (92)

1. Horecker B.L., Mehler A.H. Carbohydrate metabolism. Annu. Rev. Biochem. 1955, 24:207-274.
2. Wood T. The Pentose Phosphate Pathway 1985, Academic Press.
3. Samland A.K., Sprenger G.A. Transaldolase: from biochemistry to human disease. Int. J. Biochem. Cell Biol. 2009, 41:1482-1494.
4. Perl A. The pathogenesis of transaldolase deficiency. IUBMB Life 2007, 59:365-373.
5. Cooper R.A., Bunn H.F. Hemolytic anemias. Harrison's Principles of Internal Medicine 1991, 1531-1543. McGraw-Hill. 12th edn. J.D. Wilson (Ed.).
6. Vulliamy T., et al. The molecular basis of glucose-6-phosphate dehydrogenase deficiency. Trends Genet. 1992, 8:138-143.
7. Hirono A., et al. Identification of the binding domain for NADP+ of human glucose-6-phosphate dehydrogenase by sequence analysis of mutants. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:10015-10017.
8. Vulliamy T.J., et al. Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:5171-5175.
9. Ruwende C., Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J. Mol. Med. 1998, 76:581-588.
10. Meloni L., et al. Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease. J. Inherit. Metab. Dis. 2008, 31:412-417.
11. Pandolfi P.P., et al. Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. EMBO J. 1995, 14:5209-5215.
12. Martin P.R., et al. Molecular genetics of transketolase in the pathogenesis of the Wernicke-Korsakoff syndrome. Metab. Brain Dis. 1995, 10:45-55.
13. Xu Z.P., et al. Transketolase haploinsufficiency reduces adipose tissue and female fertility in mice. Mol. Cell. Biol. 2002, 22:6142-6147.
14. Perl A., et al. Transaldolase is essential for maintenance of the mitochondrial transmembrane potential and fertility of spermatozoa. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14813-14818.
15. Hanczko R., et al. Prevention of hepatocarcinogenesis and acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J. Clin. Invest. 2009, 119:1546-1557.
16. Tylki-Szymanska A., et al. Transaldolase deficiency in two new patients with a relative mild phenotype. Mol. Genet. Metab. 2009, 97:15-17.
17. Qian Y., et al. Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing. Biochem. J. 2008, 415:123-134.
18. Geminard C., et al. Reticulocyte maturation: mitoptosis and exosome release. Biocell 2002, 26:205-215.
19. Fernandez D.R., et al. Activation of mTOR controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J. Immunol. 2009, 182:2063-2073.
20. Banki K., et al. Elevation of mitochondrial transmembrane potential and reactive oxygen intermediate levels are early events and occur independently from activation of caspases in Fas signaling. J. Immunol. 1999, 162:1466-1479.
21. Susskind B.M., et al. A pathway for the interconversion of hexose and pentose in the parasitic amoeba Entamoeba histolytica. Biochem. J. 1982, 204:191-199.
22. Feldmann S.D., et al. Pentose metabolism in Zymomonas mobilis wild-type and recombinant strains. Appl. Microbiol. Biotechnol. 1992, 38:354-361.
23. Wood T. The forward and reverse reactions of transaldolase. FEBS Lett. 1972, 25:153-155.
24. 31P-NMR experimental data from human erythrocytes. Eur. J. Biochem. 1989, 180:399-420.
25. Grossman C.E., et al. ZNF143 mediates basal and tissue-specific expression of human transaldolase. J. Biol. Chem. 2004, 279:12190-12205.
26. Antonenkov V.D., et al. Peroxisomes are oxidative organelles. Antiox. Redox Signal. 2009, 13:525-537.
27. Holmgren A., Bjornstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 1995, 252:199-208.
28. Mayes P.A. The pentose phosphate pathway and other pathways of hexose metabolism. Harper's Biochemistry 1993, 201-211. Appleton and Lange. 23rd edn. R.K. Murray (Ed.).
29. Banki K., et al. Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression. J. Biol. Chem. 1996, 271:32994-33001.
30. Ni T.-C., Savageau M.A. Application of biochemical systems theory to metabolism in human red blood cells. Signal propagation and accuracy of representation. J. Biol. Chem. 1996, 271:7927-7941.
31. Follstad B.D., Stephanopoulos G. Effect of reversible reactions on isotope label redistribution - analysis of the pentose phosphate pathway. Eur. J. Biochem. 1998, 252:360-371.
32. Baquer N.Z., et al. Aspects of carbohydrate metabolism in developing brain. Dev. Med. Child Neurol. 1977, 19:81-104.
33. Thom E., et al. Sweet pepper plastids: enzymic equipment, characterization of the plastidic oxidative pentose-phosphate pathway, and transport of phosphorylated intermediates across the envelope membrane. Planta 1998, 204:226-233.
34. Banki K., et al. Molecular ordering in HIV-induced apoptosis: oxidative stress, activation of caspases, and cell survival are regulated by transaldolase. J. Biol. Chem. 1998, 273:11944-11953.
35. Verhoeven N.M., et al. Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway. Am. J. Hum. Genet. 2001, 68:1086-1092.
36. Grossman C.E., et al. Deletion of serine 171 causes misfolding, proteasome-mediated degradation, and complete deficiency of human transaldolase. Biochem. J. 2004, 382:725-731.
37. Dalton T.P., et al. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic. Biol. Med. 2004, 37:1511-1526.
38. Will Y., et al. gamma-Glutamyltranspeptidase-deficient knockout mice as a model to study the relationship between glutathione status, mitochondrial function, and cellular function. Hepatology 2000, 32:740-749.
39. Lachaise F., et al. Relationship between posttranslational modification of transaldolase and catalase deficiency in UV-sensitive repair-deficient Xeroderma pigmentosum fibroblasts and SV40-transformed human cells. Free Radic. Biol. Med. 2001, 30:1365-1373.
40. Nagata S., Golstein P. The Fas death factor. Science 1995, 267:1449-1456.
41. Drappa J., et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 1996, 335:1643-1649.
42. Banki K., et al. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J. Exp. Med. 1994, 180:1649-1663.
43. Colombo E., et al. Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. J. Clin. Invest. 1997, 99:1238-1250.
44. Esposito M., et al. Human transaldolase and cross-reactive viral epitopes identified by autoantibodies of multiple sclerosis patients. J. Immunol. 1999, 163:4027-4032.
45. Niland B., et al. CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J. Immunol. 2005, 175:8365-8378.
46. Niland B., et al. Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients. J. Immunol. 2010, 184:4025-4032.
47. Martin R., et al. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992, 10:153-187.
48. Rum S., et al. Identification of seroreactive proteins in the culture filtrate antigen of Mycobacterium avium paratuberculosis human isolates to sera from Crohn's disease patients. FEMS Immunol. Med. Microbiol. 2009, 58:127-137.
49. Merrill J.E., et al. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 1993, 151:2132-2141.
50. Kugler P. Glucose-6-phosphate dehydrogenase is enriched in oligodendrocytes of the rat spinal cord. Enzyme histochemical and immunocytochemical studies. Histochemistry 1994, 101:143-153.
51. Andrade F., et al. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 1998, 8:451-460.
52. Gergely P.J., et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002, 46:175-190.
53. Fernandez D.R., Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?. Discov. Med. 2010, 9:173-178.
54. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
55. Acacio B.D., et al. Evaluation of a large cohort of men presenting for a screening semen analysis. Fertil. Steril. 2000, 73:595-597.
56. Valayannopoulos V., et al. Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease. J. Pediatr. 2006, 149:713-717.
57. Balasubramaniam S., et al. Novel heterozygous mutations in TALDO1 gene causing transaldolase deficiency and early infantile liver failure. J. Pediat. Gastroenterol. Nutr. 2011, 52:113-116.
58. Stefan N., et al. Causes and metabolic consequences of fatty liver. Endocr. Rev. 2008, 29:939-960.
59. Diehl A.M. Nonalcoholic steatohepatitis. Semin. Liver Dis. 1999, 19:221-229.
60. Ahn J., Flamm S.L. Hepatocellular carcinoma. Disease-a-Month 2004, 50:556-573.
61. Larson A.M., et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1364-1372.
62. Rabinowitz J.D., White E. Autophagy and metabolism. Science 2010, 330:1344-1348.
63. Moreadith R.W., Lehninger A.L. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J. Biol. Chem. 1984, 259:6215-6221.
64. Qian S., et al. Deficiency in cytosolic malic enzyme does not increase acetaminophen-induced hepato-toxicity. Basic Clin. Pharmacol. Toxicol. 2008, 103:36-42.
65. Kabashima T., et al. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5107-5112.
66. Vas G., et al. Study of transaldolase deficiency in urine samples by capillary LC-MS/MS. J. Mass Spectrom. 2005, 41:463-469.
67. Sochor M., et al. Changes in pathways of pentose phosphate formation in relation to phosphoribosyl pyrophosphate synthesis in the developing rat kidney. Effects of glucose concentration and electron acceptors. J. Dev. Physiol. 1989, 12:135-143.
68. Galvez A.S., et al. Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis: differential effects of sorbitol and mannitol. J. Biol. Chem. 2003, 278:38484-38494.
69. Kuntzen C., et al. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res. 2005, 65:6780-6788.
70. Anna C.H., et al. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice. Toxicol. Appl. Pharmacol. 2003, 190:135-145.
71. Thompson M.D., Monga S.P. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007, 45:1298-1305.
72. Fodde R., Brabletz T. Wnt/[beta]-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007, 19:150-158.
73. Essers M.A.G., et al. Functional interaction between {beta}-catenin and FOXO in oxidative stress signaling. Science 2005, 308:1181-1184.
74. Bengochea A., et al. Common dysregulation of Wnt//Frizzled receptor elements in human hepatocellular carcinoma. Br. J. Cancer 2008, 99:143-150.
75. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 2002, 4:E131-E136.
76. Hess J., et al. AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci. 2004, 117:5965-5973.
77. Parola M., et al. HNE interacts directly with JNK isoforms in human hepatic stellate cells. J. Clin. Invest. 1998, 102:1942-1950.
78. Spycher S., et al. 4-Hydroxy-2,3-trans-nonenal induces transcription and expression of aldose reductase. Biochem. Biophys. Res. Commun. 1996, 226:512-516.
79. Nguyen M.H., Keeffe E.B. Screening for hepatocellular carcinoma. J. Clin. Gastroenterol. 2002, 35:S86-S91.
80. de La Coste A., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8847-8851.
81. Basta P.V., et al. Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck. Cancer Detect. Prev. 2008, 32:200-208.
82. Lee W.M. Acetaminophen and the U.S. Acute Liver Failure S tudy Group: lowering the risks of hepatic failure. Hepatology 2004, 40:6-9.
83. Ni R., et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp. Cell Res. 1994, 215:332-337.
84. Park S.M., et al. CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia. Apoptosis 2008, 13:41-51.
85. Hentze H., et al. CD95-Mediated murine hepatic apoptosis requires an intact glutathione status. Hepatology 1999, 30:177-185.
86. Leist M., et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 1997, 185:1481-1486.
87. Price N.E., Cook P.F. Kinetic and chemical mechanisms of the sheep liver 6-phosphogluconate dehydrogenase. Arch. Biochem. Biophys. 1996, 336:215-223.
88. Kaloyianni M., Kalomenopoulou M. Regulation and rate of the hexose monophosphate shunt in Rana ridibunda erythrocytes. Comp. Biochem. Physiol. B Comp. Biochem. 1990, 95:287-294.
89. Madia A.M., et al. 8-Azaguanine and flavinogenesis in Eremothecium ashbyii. Biochim. Biophys. Acta 1975, 385:51-57.
90. Almeida A., et al. Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:15294-15299.
91. Clementi E., et al. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7631-7636.
92. Desai B.N., et al. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:4319-4324.